Focus Partners Advisor Solutions LLC Purchases 3,152 Shares of IQVIA Holdings Inc. $IQV

Focus Partners Advisor Solutions LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 51.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,336 shares of the medical research company’s stock after buying an additional 3,152 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in IQVIA were worth $2,104,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after buying an additional 159,899 shares during the period. Geode Capital Management LLC lifted its position in shares of IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after buying an additional 24,453 shares during the period. JPMorgan Chase & Co. lifted its position in shares of IQVIA by 16.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after buying an additional 528,753 shares during the period. Alliancebernstein L.P. lifted its position in shares of IQVIA by 1.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after buying an additional 41,643 shares during the period. Finally, Boston Partners bought a new position in shares of IQVIA during the 3rd quarter worth approximately $676,698,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of several analyst reports. Mizuho set a $215.00 target price on IQVIA in a research report on Monday, February 23rd. HSBC set a $210.00 target price on IQVIA in a research report on Wednesday, June 3rd. Truist Financial cut their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Morgan Stanley set a $225.00 target price on IQVIA in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada started coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $224.13.

IQVIA Trading Down 2.1%

Shares of IQV opened at $182.28 on Thursday. The stock has a fifty day moving average price of $173.18 and a two-hundred day moving average price of $194.08. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a 52-week low of $153.01 and a 52-week high of $247.04. The company has a market cap of $30.42 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 1.60 and a beta of 1.21.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its board has approved a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.